Improvement of vanishing bile duct syndrome with hyperlipidemia

Clin J Gastroenterol. 2022 Aug;15(4):784-790. doi: 10.1007/s12328-022-01650-4. Epub 2022 Jul 8.

Abstract

A 75-year-old man was admitted to our hospital with acute onset of marked jaundice, elevated liver enzymes, and hyperlipidemia. He had been taking clopidogrel and pemafibrate for 3 months. He tested negative for autoantibodies and hepatitis-causing viruses. Gadoxetate-enhanced magnetic resonance imaging showed diffusely hypointense liver parenchyma in the hepatobiliary phase, with no appreciable excretion of gadoxetate into the biliary system. Histological examination of a liver specimen revealed disappearance of the bile ducts in the portal area and decreased expression of organic transporting polypeptide 1B3 on immunostaining. The patient was diagnosed with drug-induced vanishing bile duct syndrome and treated with ursodeoxycholic acid. The signs of liver dysfunction shown on blood chemistry tests improved spontaneously. After the acute hepatitis and lipid abnormalities had improved, repeat liver biopsy and gadoxetate-enhanced magnetic resonance imaging revealed improvement of the vanishing bile duct syndrome and recovery of the expression of organic transporting polypeptide 1B3. The reduction of OATP1B3 expression might be involved in the development of vanishing bile duct syndrome.

Keywords: Drug-induced liver injury; Hyperlipidemia; Jaundice; Vanishing bile duct syndrome.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Bile Duct Diseases* / chemically induced
  • Bile Duct Diseases* / complications
  • Bile Duct Diseases* / pathology
  • Bile Ducts / pathology
  • Bile Ducts, Intrahepatic / pathology
  • Cholestasis* / etiology
  • Humans
  • Hyperlipidemias* / complications
  • Hyperlipidemias* / pathology
  • Liver Diseases* / complications
  • Male